Evidence from pivotal trials, such as the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose) and CANVAS (Canagliflozin Cardiovascular Assessment Study) studies, underscores the kidney benefits of SGLT2is, highlighting significant reductions in the progression of kidney disease and CV mortality[70,71]
Do not use the discolored medication if unsure and contact your healthcare professional for proper guidance regarding any potential concerns and obtain a new prescription if necessary
Lilly has not yet submitted an NDA
Jody Dushay, an endocrinologist at Beth Israel Deaconess Medical Center and an assistant professor of medicine at Harvard Medical School, said Friday
Supportive secondary endpoints were semaglutide plasma concentration 24 h after last dose at SS ( C tau, 24h,SS ) and time to maximum semaglutide plasma concentration at SS ( t max, 024h,SS )